2025 · 4th Quarter (Oct 1 - Dec 31)

STEALTH BIOTHERAPEUTICS INC.

Filed by STEALTH BIOTHERAPEUTICS INC..

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 20, 2026
Income: Not reported
Expenses: $110,000.00
Registrant: STEALTH BIOTHERAPEUTICS INC.
Client: STEALTH BIOTHERAPEUTICS INC.
Filing UUID: 94ff4b50-86f0-4d63-b12b-35c34bb1b222
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025FDA Rare Disease Innovation Hub Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256)

Literal federal measure citations: H.R. 1262, S. 932, H.R. 1532, S. 822, H.R. 4121, S. 2256

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.